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In laboratories that study basic biol­
ogy, faulty microarray data can waste 
huge amounts of time, money, and 
effort. In the clinic, however, where the 
hope is that microarrays can be used 
for disease diagnosis and prognosis, 
such data could make the difference 
between life and death. Microarrays 
hold large appeal because of their 
ability to simultaneously assess the 
activity of thousands of genes. But 
questions about the technology’s reli­
ability have clouded the enterprise.
To probe the issue of microarray 
reproducibility, the US Food and Drug 
Administration (FDA) has launched a 
large effort to scrutinize microarray 
technology and how it is used. The 
enterprise, called the MicroArray Qual­
ity Control (MAQC) project, involved 
137 participants from 51 organizations 
representing academia, industry, and 
government. The first set of results 
from this project—reported in six 
papers in Nature Biotechnology’s Sep­
tember issue—address the similarity 
among lists of differentially expressed 
genes. The consortium gauged the 
performance of seven micro­
array platforms, each of which 
queried the abundance of more 
than 12,000 genes in the same 
two RNA samples (one from 
a mixture of human cell lines, 
A; the other from human brain 
tissue, B). Each platform was 
tested at three separate labo­
ratories and each laboratory 
assayed samples A and B, as 
well as mixtures of the two in 
different ratios, five times. The 
results reveal that the distinct 
platforms and test sites per­
formed comparably, generat­
ing similar lists of genes whose 
activity differed by at least a 
factor of two between the two 
RNA samples.
“It probably is the most rigorous 
and thorough performance evalua­
tion to assess any technology devel­
oped in the last 20 years,” says Lajos 
Pusztai, of the MD Anderson Cancer 
Center in Houston, a MAQC project 
member. “The bottom line is that 
microarrays are very reliable.” Addi­
tional investigations should help to 
resolve the many remaining chal­
lenges surrounding the use of micro­
arrays in the lab and, eventually, the 
clinic.
Investigators who were not part of 
the MAQC study are also enthusias­
tic. “They’ve done this experiment 
that everyone wanted the answer to 
but no one could do—it was just too 
expensive and unwieldy to organize all 
the participants,” says Charles Kim, 
of the University of California, San 
Francisco (UCSF). “The thing that’s 
really neat about this is that it’s the 
most comprehensive study done to 
assess reproducibility and it involves 
the microarray companies directly. 
The level of expertise is extremely 
high. That eliminates a major source 
of error…the one that arises when 
you don’t use the arrays properly.”
Biologists will benefit from the 
reports. “There’s a lot of word on the 
street that some platforms are much 
better than others,” says Katherine 
Pollard, of UC Davis, “but it seems 
like they all did really well.” Given that 
the platforms performed compara­
bly, scientists can consider issues 
such as cost, design flexibility, den­
sity of arrays, and ease of use when 
choosing a product, says David Erle 
of UCSF. “Each platform has advan­
tages, depending on the experiment,” 
he says. The RNA samples used in 
the MAQC study are available com­
mercially and in sufficient supply to 
enable researchers to use them as 
reference standards for at least sev­
eral years.
Toward Reproducibility
In principle, microarrays can reveal 
genes whose expression changes 
under particular conditions. Many 
researchers were unsettled by reports 
that different microarray platforms or 
research groups generated lists of 
differentially expressed genes that 
correlated poorly. In particular, the 
image of a published Venn diagram 
(see Figure 1) showing a very small 
degree of overlap had a big impact 
on many investigators, according 
to sources interviewed for this arti­
cle: Only 4 of 185 genes identified 
as differentially expressed were 
pinpointed by all three microarray 
platforms tested. Other studies 
suggested more similarity among 
results from various platforms or 
different labs, but worries persisted. 
“People were saying that microar­
ray technology itself was not very 
reproducible—that you couldn’t get 
a reproducible gene list even within 
the same lab on the same platform 
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A large study by the MAQC consortium has established that different DNA microarray plat-
forms can generate reproducible lists of differentially expressed genes. Now scientists are 
grappling with the challenges of moving the technology toward the clinic.
Figure 1. The Diagram that Launched MAQC 
A Venn diagram of genes classified as differentially ex­
pressed by three different microarray platforms. Of the 
185 genes tested, only 4 were identified as having altered 
expression by all three platforms. (Adapted from P.K. Tan 
et al., 2003, Nucl. Acids Res. 31, 5676–5684).Cell 127, November 17, 2006 ©2006 Elsevier Inc. 657
with the same samples,” notes Fed­
erico Goodsaid, of the Center for Drug 
Evaluation and Research at the FDA.
The disparity between the MAQC 
results and those of earlier studies 
reporting little concordance between 
gene lists could arise from several 
sources. Unlike previous efforts, the 
MAQC project took steps to rule out 
problems that stem from using differ­
ent sequences to represent a particu­
lar gene (alternative splicing and cross­
hybridization can generate faulty data 
if this source of error is not minimized). 
But the main explanation for the 
improved overlap was the technique 
used to analyze the data, say consor­
tium members. “When we make lists of 
interesting genes, we should use fold­
change along with some less stringent 
statistical criteria, like a reasonable p 
value” says MAQC study participant 
Roderick Jensen, of the University of 
Massachusetts, Boston. “Recently 
what’s been done [in the field] is to use 
the statistical criteria foremost.”
The MAQC project chose genes in 
two steps. First the researchers calcu­
lated the average ratio of gene expres­
sion in sample B to sample A for each 
gene on each platform and chose 
those whose expression levels differed 
by at least a factor of two. Then they 
applied statistics to examine the scat­
ter in the data that would identify mem­
bers of the list whose expression pat­
terns would occur less than one time in 
1000 by chance alone if samples A and 
B did not differ. 
Other elements, too, contributed to 
the reproducibility. For example, the 
labs that performed the assays had 
significant experience with the plat­
form they were testing. “The compa­
nies controlled the use of their own 
platforms so the MAQC project had 
the best of the best working on it,” says 
Kim. “Most labs can do one platform or 
at the most two very well. [The MAQC 
organizers] used the right approach—
involving all the companies rather than 
trying to do it all themselves. You can 
learn to do PCR well in a month. But 
with microarrays, it can take years.” 
Jensen emphasizes that “the MAQC 
study was not about whether one study 
was better than another. It was about 
whether the lack of reproducibility in 658 Cell 127, November 17, 2006 ©2006previous studies was due to deficien­
cies in the DNA microarray technology. 
The answer should be a clear no.”
Caveats and Limitations
Scientists welcome the MAQC consor­
tium data but also advise caution. The 
findings represent the ceiling of what 
to expect from the technology at the 
moment, says Margaret Cam, Director 
of the Genomics Core Laboratory of 
the National Institute of Diabetes and 
Digestive and Kidney Diseases and 
senior author on the highly cited paper 
with the arresting Venn diagram (see 
Figure 1). The dissimilar RNA samples 
used in the MAQC study—from cell 
lines and brain tissue—have a large sig­
nal­to­noise ratio, she points out. This 
is not the case for other cross­platform 
comparisons or for many applications 
of microarrays. The relative emphasis 
on fold­change during analysis might 
not generate as reliable results from 
the types of samples that researchers 
generally want to evaluate, she and 
others say. Meaningful gene expres­
sion changes between, for example, 
cancerous and noncancerous tissue 
are likely to be subtle whereas the vari­
ation among random healthy individu­
als will be great. “In any measurement, 
the error bars are a combination of 
multiple sources of error—systematic 
error and biological variability,” says 
John Quackenbush, of the Dana Far­
ber Cancer Institute in Boston. “In the 
MAQC study, they established that the 
technology is robust. But they haven’t 
shown that you can extend this and 
apply it to real biological samples.”
Several researchers expressed 
concern about the message some 
scientists might take home regard­
ing the analysis. “At least two of the 
six papers say something that is likely 
to be interpreted by most life scien­
tists as saying you should select your 
genes using the fold change rather 
than the p value,” says Sorin Draghici, 
Director of the Bioinformatics Core, 
Karmanos Cancer Institute in Detroit. 
“There is nothing wrong with the 
[MAQC consortium’s] statements, but 
the way they likely will be read by most 
life scientists is a problem. It has the 
potential to bring the whole field back 
by 10 years or so.” Elsevier Inc.MAQC project participants acknowl­
edge that the sample choice restricts 
indiscriminate application of their ana­
lytical methods but underscore that the 
“samples were deliberately chosen to 
have large numbers of genes whose 
expression levels were different,” says 
Jensen. Furthermore, one of the six 
Nature Biotechnology papers reports 
a comparison study of four microarray 
platforms using RNA from rats exposed 
to three chemicals, points out MAQC’s 
leader, Leming Shi, of FDA’s National 
Center for Toxicological Research 
in Arkansas. The conclusions were 
“largely consistent” with those derived 
from RNA samples A and B used for 
the main study, he notes.
Into the Clinic, Back to the Bench
The MAQC project is one of several 
enterprises aimed at some aspect of 
standardizing and sharing microar­
ray data. The External RNA Controls 
Consortium (ERCC), an industry­led 
group hosted by the National Institute 
of Standards and Technology (NIST), is 
developing new analytic approaches, 
protocols, and control RNAs that can 
be “spiked in” to any sample. In con­
trast to the MAQC project, which 
assessed the technical reproducibility 
of microarrays, the tools being devel­
oped by ERCC should help scientists 
in their daily experiments. “If I run 
the MAQC reference samples in the 
lab, I can compare the results I got at 
home with [those of the MAQC con­
sortium] and establish the lab’s profi­
ciency,” says Marc Salit of NIST. “But 
that doesn’t tell me how much confi­
dence I should have in the results from 
my own biological samples.” ERCC 
has also published guidelines for the 
use of external RNA controls in gene 
expression analyses—a document that 
should allow people to use the spike­
ins accurately and well—and that might 
help inform eventual regulatory recom­
mendations,” says Salit.
Other efforts, such as those by 
the Microarray Gene Expression 
Data (MGED) Society, are laying the 
groundwork for the widespread use 
of microarray data. Such efforts may 
contribute to the push toward licens­
ing of expression­based microarray 
products for use in the clinic, says 
Salit, who is on the MGED board. 
This venture, a collaboration between 
academia and industry, is focusing on 
tools and standards to promote data 
sharing. Such sharing could be enor­
mously valuable because, for instance, 
it could allow researchers to mine a 
huge set of data for information about 
biological questions that the investiga­
tors who generated the data did not 
ask. Furthermore, it should establish 
the means for investigators to “report 
data to the FDA in a way that the FDA 
can verify the claims being made about 
the new drug application or the in vitro 
device application,” says Salit.
The FDA’s interest in microarrays 
springs from tantalizing results sug­
gesting that this technology can be 
commandeered to personalize medi­
cine. A number of studies have reported 
that certain gene “signatures” predict 
particular clinical outcomes. Typically, 
researchers use one set of patients to 
identify a gene­expression pattern that 
appears to correspond to a measure 
of interest, such as 5­year survival, 
response to a drug, or whether a par­
ticular compound induces side effects. 
Then this genetic signature is validated 
on other groups of patients. In princi­
ple, physicians can use this information 
to guide treatment decisions. However, 
patient groups are often too small to 
obtain clear answers.
No expression­based microar­
ray products are currently approved 
or licensed by the FDA. “To use 
[expression­based] profiles for clini­
cally useful diagnostics, two things 
will be required: confidence in the 
technology and confidence in the 
analysis methods that are used to 
classify or distinguish the samples,” 
says Jensen. Phase 1 of the MAQC 
project focused on the technical 
performance of microarrays. Now 
the question is how microarrays can 
help to make a diagnosis or choose 
a therapy. The goals of MAQC Phase 
2 “are not yet clearly defined,” says 
Jensen, but they will evaluate analyti­
cal methods for generating and vali­
dating gene signatures for the clinic, using several dozen patient data sets 
from all over the world. The project 
will try to determine “under what 
circumstances you should use what 
analytical tools to generate a reliable 
signature—defined by its predictive 
value for whatever it is you’re trying to 
predict,” says Goodsaid.
The next phase will also probe how 
differences in sample handling—such 
as the biopsy method and RNA prepa­
ration—contribute to other sources of 
variability, according to a document 
from the MAQC Phase 2 Clinical Work­
ing Group. The results should “assist 
the FDA in understanding the perform­
ance characteristics and limitations of 
multigene clinical outcome predictors 
using RNA from clinical specimens.” 
Shi notes, “Every technology, including 
microarrays, has its capabilities and 
limitations. Identifying those limitations 
will help the proper applications of the 
microarray technology.” The lessons 
learned from MAQC Phases 1 and 2 
will be incorporated into a draft best 
practice document, says Weida Tong 
of FDA’s National Center for Toxicologi­
cal Research. “That will form the basis 
for discussion with the industry. Then 
we’ll finalize the document, which will 
be used as formal guidance for how to 
submit data to FDA.”
While the FDA works toward estab­
lishing its recommendations, physi­
cians in other countries are already 
using microarrays to direct therapies. 
In Europe, where diagnostic tests are 
not subject to regulatory approval, a 
microarray intended to evaluate breast 
cancer prognosis is on the market. 
This tool, called Mammaprint, is pro­
duced by the Dutch company Agen­
dia, whose chief scientific officer, 
René Bernards, is a leading cancer 
biologist at the Netherlands Cancer 
Institute in Amsterdam. Bernards was 
the senior author on a 2002 landmark 
paper in the New England Journal of 
Medicine reporting a gene­expres­
sion signature that predicted survival 
in 295 breast cancer patients. That 
work has been validated in a study of 
307 patients from five European can­Cell 127, Novcer centers, published this September 
in the Journal of the National Cancer 
Institute. Although Mammaprint is not 
yet licensed by the FDA, discussions 
between Agendia and the agency are 
“now in an advanced stage,” says Ber­
nards. “Regulatory approval by the 
FDA is a definite possibility.”
Agendia bypasses some of the big­
gest sources of error in using microar­
rays by performing the tests in a cen­
tral lab. “That allows us to maximally 
control the quality of the results,” says 
Bernards, avoiding problems that arise 
from different methods of sample han­
dling and analysis. “Our model is not 
that we perform the tests in local hos­
pitals,” he says. “It’s not to be sold as 
a kit.” To do that, he says, the technol­
ogy would need to address a range of 
quality­control issues. “Every aspect 
of the process needs to be so robust, 
it’s idiot proof. Microarray technology 
today is certainly not idiot proof. You 
really need to know what you’re doing.” 
Bernards predicts that microarray 
developers will meet these challenges 
sometime in the next 10 years.
Moving the technology to the point 
where clinical labs in hospitals can 
perform the tests would also benefit 
researchers who work on basic bio­
logical problems. “As people … make 
these techniques robust enough that 
they can get into clinical labs, that will 
presumably make them robust enough 
for researchers who don’t have a lot of 
microarray expertise,” says Erle. Other 
improvements that will help in health­
care settings will also spill over into 
academia, he says. For example, the 
ability to handle multiple samples simul­
taneously would be a big step forward: 
Measuring the expression of 50 to 100 
genes on 100 samples at once would 
be useful in the clinic, says Erle. Right 
now, a standard microarray tests many 
more genes—but with only one sample 
at a time. “I find people compromis­
ing on experimental design all the time 
because of cost issues,” says Erle. “If 
the clinical labs push ahead with multi­
ple sample handling, that could have a 
big effect on basic research.”
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